JP2012523429A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523429A5 JP2012523429A5 JP2012504871A JP2012504871A JP2012523429A5 JP 2012523429 A5 JP2012523429 A5 JP 2012523429A5 JP 2012504871 A JP2012504871 A JP 2012504871A JP 2012504871 A JP2012504871 A JP 2012504871A JP 2012523429 A5 JP2012523429 A5 JP 2012523429A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- use according
- alkyl
- pulmonary fibrosis
- kinase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16790509P | 2009-04-09 | 2009-04-09 | |
| US61/167,905 | 2009-04-09 | ||
| US23574009P | 2009-08-21 | 2009-08-21 | |
| US61/235,740 | 2009-08-21 | ||
| PCT/US2010/030420 WO2010118250A2 (en) | 2009-04-09 | 2010-04-08 | Methods and compositions of pi-3 kinase inhibitors for treating fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012523429A JP2012523429A (ja) | 2012-10-04 |
| JP2012523429A5 true JP2012523429A5 (enExample) | 2013-05-16 |
Family
ID=42936877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012504871A Pending JP2012523429A (ja) | 2009-04-09 | 2010-04-08 | 線維症を処置するための方法およびｐｉ−３キナーゼインヒビターの組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120046333A1 (enExample) |
| EP (1) | EP2416771A4 (enExample) |
| JP (1) | JP2012523429A (enExample) |
| KR (1) | KR20120018761A (enExample) |
| CN (1) | CN102395363A (enExample) |
| AU (1) | AU2010234360A1 (enExample) |
| BR (1) | BRPI1015940A2 (enExample) |
| CA (1) | CA2754343A1 (enExample) |
| MX (1) | MX2011010631A (enExample) |
| WO (1) | WO2010118250A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727478A (zh) * | 2012-06-14 | 2012-10-17 | 合肥博太医药生物技术发展有限公司 | 视黄酸及其衍生物在制备防治肾纤维化药物中的应用 |
| TWI736135B (zh) | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| EP3099380B1 (en) | 2014-01-28 | 2021-08-11 | Buck Institute for Research on Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| CN110917351A (zh) * | 2018-09-20 | 2020-03-27 | 华中科技大学同济医学院附属同济医院 | Mbd2抑制剂在预防和治疗纤维化疾病中的用途 |
| JP2022065212A (ja) * | 2019-02-28 | 2022-04-27 | 国立大学法人京都大学 | 組織線維化による疾患の予防又は治療のための医薬 |
| EP3946330A1 (en) * | 2019-03-29 | 2022-02-09 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders |
| US20230416782A1 (en) * | 2020-12-10 | 2023-12-28 | Children's Hospital Medical Center | Enhanced nanoparticle delivery systems |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004075917A1 (ja) * | 2003-02-28 | 2004-09-10 | Toudai Tlo, Ltd. | 器官または組織の線維化抑制剤 |
| WO2007008200A1 (en) * | 2004-07-09 | 2007-01-18 | Prolx Pharmaceuticals Corp. | Wortmannin analogs and methods of using same in combination with chemotherapeutic agents |
| WO2006125539A2 (en) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
| CN101180055A (zh) * | 2005-05-27 | 2008-05-14 | 拜耳医药保健股份公司 | 用于治疗疾病的包含二芳基脲的组合治疗 |
| ATE536181T1 (de) * | 2005-12-30 | 2011-12-15 | Univ Arizona | Metabolite von wortmannin-analogen und verwendungsverfahren dafür |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
-
2010
- 2010-04-08 MX MX2011010631A patent/MX2011010631A/es not_active Application Discontinuation
- 2010-04-08 CN CN2010800151213A patent/CN102395363A/zh active Pending
- 2010-04-08 US US13/262,906 patent/US20120046333A1/en not_active Abandoned
- 2010-04-08 WO PCT/US2010/030420 patent/WO2010118250A2/en not_active Ceased
- 2010-04-08 KR KR1020117026616A patent/KR20120018761A/ko not_active Ceased
- 2010-04-08 JP JP2012504871A patent/JP2012523429A/ja active Pending
- 2010-04-08 EP EP10762450A patent/EP2416771A4/en not_active Withdrawn
- 2010-04-08 CA CA2754343A patent/CA2754343A1/en not_active Abandoned
- 2010-04-08 AU AU2010234360A patent/AU2010234360A1/en not_active Abandoned
- 2010-04-08 BR BRPI1015940A patent/BRPI1015940A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523429A5 (enExample) | ||
| JP2014508753A5 (enExample) | ||
| JP2011137045A5 (enExample) | ||
| JP2011518833A5 (enExample) | ||
| JP2013505929A5 (enExample) | ||
| JP2008513467A5 (enExample) | ||
| JP2011525173A5 (enExample) | ||
| JP2013010749A5 (ja) | カルバゾール化合物 | |
| JP2010530897A5 (enExample) | ||
| JP2012233172A5 (enExample) | ||
| JP2012144574A5 (enExample) | ||
| JP2015512946A5 (enExample) | ||
| JP2010537034A5 (enExample) | ||
| CN111511749A (zh) | 具有大环分子结构的化合物及其用途 | |
| JP2013100341A5 (enExample) | ||
| JP2011105738A5 (enExample) | ||
| JP2013060411A5 (ja) | カルバゾール化合物 | |
| JP2008531734A5 (enExample) | ||
| JP2012087114A5 (ja) | カルバゾール誘導体 | |
| JP2019516739A5 (enExample) | ||
| JP2010500432A5 (enExample) | ||
| JP2010116441A5 (enExample) | ||
| JP2014527532A5 (enExample) | ||
| JP2010529994A5 (enExample) | ||
| AR070411A1 (es) | Forma polimorfica de n-[3-terc-butil-1-(3-cloro-4-hidroxifenil)-1h-pirazol-5-il]-n'-{2-[(3-{2-[(2-hidroxietil)sulfanil]fenil}[1,2,4]triazolo[4,3-a]piridin-6-il)sulfanil]bencil}urea, composiciones farmaceuticas que la comprenden y metodo de preparacion |